These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Olanow CW; Obeso JA; Stocchi F Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589 [TBL] [Abstract][Full Text] [Related]
8. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? Mercuri NB; Bernardi G Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832 [TBL] [Abstract][Full Text] [Related]
10. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614 [TBL] [Abstract][Full Text] [Related]
11. An update on the treatment of Parkinson's disease. Jankovic J Mt Sinai J Med; 2006 Jul; 73(4):682-9. PubMed ID: 16878274 [TBL] [Abstract][Full Text] [Related]
12. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. Delfino MA; Stefano AV; Ferrario JE; Taravini IR; Murer MG; Gershanik OS Behav Brain Res; 2004 Jul; 152(2):297-306. PubMed ID: 15196797 [TBL] [Abstract][Full Text] [Related]
13. Parkinson's disease: diagnosis and treatment. Rao SS; Hofmann LA; Shakil A Am Fam Physician; 2006 Dec; 74(12):2046-54. PubMed ID: 17186710 [TBL] [Abstract][Full Text] [Related]
14. [Current preclinical findings on substances against Parkinson's disease]. Gerlach M; Riederer P Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677 [TBL] [Abstract][Full Text] [Related]
15. Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease. Koutsilieri E; Riederer P Parkinsonism Relat Disord; 2007; 13 Suppl 3():S329-31. PubMed ID: 18267259 [TBL] [Abstract][Full Text] [Related]
16. When and how should treatment be started in Parkinson disease? Lang AE Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313 [TBL] [Abstract][Full Text] [Related]
17. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Hallett PJ; Standaert DG Pharmacol Ther; 2004 May; 102(2):155-74. PubMed ID: 15163596 [TBL] [Abstract][Full Text] [Related]
18. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities. Jenner P Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676 [TBL] [Abstract][Full Text] [Related]